Harry Spoelstra
Impact of COVID-19 on corneal endothelial density and morphology: a cross-sectional study in convalescent patients 🚨One documented COVID infection was linked to a sparser, less orderly corneal endothelium, fewer cells, messier mosaic, but patients still saw the same and their corneas were not swollen. ➡️Interesting Chinese cross-sectional study: 378 convalescent patients (≥2 months after PCR-confirmed symptomatic infection) vs 382 with no known COVID history. Mean age 64.8. Fujian, after the Omicron wave (Aug 2022–May 2023). ➡️Study found that recovered COVID patients had a thinner, less orderly corneal endothelium: - ECD: 2,560 vs 2,736 cells/mm² (p < 0.001), about 176 fewer cells/mm² (~6%) - HEX: 48.9% vs 50.6% (p = 0.005) - Larger, more variable cells (higher SD-Area, average cell area, MAX; all p < 0.001) - No difference in corneal thickness (530 vs 528 µm) or best-corrected acuity (both groups ~0.4) ➡️COVID history and older age independently predicted lower cell density. The same pattern held across age, sex, cataract/retina diagnosis, and hypertension/diabetes. ➡️Authors point to ACE2-related endothelial injury, cytokines, and oxidative stress. ➡️Cells do not regenerate, so the change, if confirmed, is a reserve loss, not a temporary swell. ➡️Reinfection / vaccines: Not studied. Vaccination status was unrecorded and listed as a limitation. ➡️Does this mean worse vision after COVID? Not in this cohort. Looking at the science available, vision fails from endothelium only when the pump/barrier collapses and the cornea clouds with oedema. That usually happens around 400–700 cells/mm², with concern rising below ~1,000–2,000. A mean here of 2,560 is still in the functional range for older adults. Same thickness + same acuity further demonstrated no group-level decompensation. Poorer acuity in some subgroups tracked more with cataracts and age than with these cell counts. ➡️Commentary: So, the microscope signal is consistent and large enough to take seriously. A 6% density drop with a slightly messier mosaic is however a reserve problem, not proof that COVID blurred the average recovered patient’s sight. Furthermore, the study design cannot prove the virus caused the drop: no pre-COVID baseline, possible hidden infections in “never COVID” controls, no severity or lineage data, and no vaccine data. Subtle quality-of-vision issues (glare, contrast, fluctuating blur) were not tested. The bigger question: multiple Covid-19 hits? A single COVID recovery is independently associated with fewer, less hexagonal corneal endothelial cells months later, without thicker corneas or worse measured acuity. The tissue that keeps the eye clear looks slightly worn, aged! Everyday vision, with this study, doesn’t change! But what with (multiple)reinfections? #SilentLongC0VID #AvoidSars2 #AvoidReinfections https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1878263/pdf
